- Home
- CELH vs EXEL Comparison
CELH vs EXEL Comparison
Compare CELH & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELH | EXEL |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 11.7B |
| IPO Year | 2008 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CELH | EXEL |
|---|---|---|
| Price | $58.08 | $44.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 21 |
| Target Price | ★ $66.19 | $46.60 |
| AVG Volume (30 Days) | ★ 4.2M | 2.6M |
| Earning Date | 05-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | 0.22 | ★ 2.78 |
| Revenue | ★ $1,318,014,000.00 | $452,477,000.00 |
| Revenue This Year | $83.24 | $13.66 |
| Revenue Next Year | $32.61 | $14.30 |
| P/E Ratio | $230.05 | ★ $16.10 |
| Revenue Growth | ★ 101.65 | N/A |
| 52 Week Low | $24.04 | $32.38 |
| 52 Week High | $66.74 | $48.74 |
Technical Indicators
Market Signals| Indicator | CELH | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 69.85 | 57.67 |
| Support Level | $41.58 | $40.50 |
| Resistance Level | $57.85 | $46.55 |
| Average True Range (ATR) | 2.05 | 1.23 |
| MACD | 0.94 | 0.19 |
| Stochastic Oscillator | 90.65 | 81.31 |
Price Performance
Historical ComparisonAbout CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.